"The results of the PREVAIL trial add to the wealth of previously published data confirming the utility of the WATCHMAN device as an option for the reduction of stroke in high risk patients," said Kenneth Stein, M.D., chief medical officer, Cardiac Rhythm Management, Boston Scientific. "WATCHMAN is the only device-based alternative to anticoagulation that has undergone rigorous scientific study. We are pleased the PREVAIL results showed low complication rates with both new and experienced operators and significantly lower complications than the early stage of the PROTECT AF trial."Data from the PREVAIL trial, complemented by the PROTECT AF four-year outcomes data, the WATCHMAN Pilot study six-year data, the ASAP study and the CAP registry data update will be submitted to support device approval by the U.S. Food and Drug Administration (FDA).
The Boston Scientific Watchman® Device Continues To Demonstrate Positive Clinical Outcomes For Patients With Atrial Fibrillation
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts